107 related articles for article (PubMed ID: 38749067)
1. Allogeneic haematopoietic cell transplantation for chronic myeloid leukaemia in Switzerland in the face of rapid development of effective drugs.
Heim D; Baldomero H; Medinger M; Masouridi-Levrat S; Schanz U; Nair G; Güngör T; Halter J; Passweg JR; Chalandon Y;
Swiss Med Wkly; 2024 May; 154():3754. PubMed ID: 38749067
[TBL] [Abstract][Full Text] [Related]
2. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.
Chhabra S; Ahn KW; Hu ZH; Jain S; Assal A; Cerny J; Copelan EA; Daly A; DeFilipp Z; Gadalla SM; Gale RP; Ganguly S; Hamilton BK; Hildebrandt GC; Hsu JW; Inamoto Y; Kanate AS; Khoury HJ; Lazarus HM; Litzow MR; Nathan S; Olsson RF; Pawarode A; Ringden O; Rowe JM; Saad A; Savani BN; Schouten HC; Seo S; Shah NN; Solh M; Stuart RK; Ustun C; Woolfrey AE; Yared JA; Alyea EP; Kalaycio ME; Popat U; Sobecks RM; Saber W
Blood Adv; 2018 Nov; 2(21):2922-2936. PubMed ID: 30396912
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors.
Nair AP; Barnett MJ; Broady RC; Hogge DE; Song KW; Toze CL; Nantel SH; Power MM; Sutherland HJ; Nevill TJ; Abou Mourad Y; Narayanan S; Gerrie AS; Forrest DL
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1437-44. PubMed ID: 25865648
[TBL] [Abstract][Full Text] [Related]
4. Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.
Warlick E; Ahn KW; Pedersen TL; Artz A; de Lima M; Pulsipher M; Akpek G; Aljurf M; Cahn JY; Cairo M; Chen YB; Cooper B; Deol A; Giralt S; Gupta V; Khoury HJ; Kohrt H; Lazarus HM; Lewis I; Olsson R; Pidala J; Savani BN; Seftel M; Socié G; Tallman M; Ustun C; Vij R; Vindeløv L; Weisdorf D
Blood; 2012 Apr; 119(17):4083-90. PubMed ID: 22408257
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party.
Radujkovic A; Dietrich S; Blok HJ; Nagler A; Ayuk F; Finke J; Tischer J; Mayer J; Koc Y; Sorà F; Passweg J; Byrne JL; Jindra P; Veelken JH; Socié G; Maertens J; Schaap N; Stadler M; Itälä-Remes M; Tholouli E; Arat M; Rocha V; Ljungman P; Yakoub-Agha I; Kröger N; Chalandon Y
Biol Blood Marrow Transplant; 2019 Oct; 25(10):2008-2016. PubMed ID: 31271884
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
7. A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation.
Shanavas M; Messner HA; Kamel-Reid S; Atenafu EG; Gupta V; Kuruvilla J; Kim DD; Uhm J; Lambie A; Ellis L; Lipton JH
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):87-92. PubMed ID: 24252361
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis.
Chaudhury S; Sparapani R; Hu ZH; Nishihori T; Abdel-Azim H; Malone A; Olsson R; Hamadani M; Daly A; Bacher U; Wirk BM; Kamble RT; Gale RP; Wood WA; Hale G; Wiernik PH; Hashmi SK; Marks D; Ustun C; Munker R; Savani BN; Alyea E; Popat U; Sobecks R; Kalaycio M; Maziarz R; Hijiya N; Saber W
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1056-1064. PubMed ID: 26964698
[TBL] [Abstract][Full Text] [Related]
9. Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase.
Xu L; Zhu H; Hu J; Wu D; Jiang H; Jiang Q; Huang X
Front Med; 2015 Sep; 9(3):304-11. PubMed ID: 26100855
[TBL] [Abstract][Full Text] [Related]
10. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
Bornhäuser M; Kröger N; Schwerdtfeger R; Schafer-Eckart K; Sayer HG; Scheid C; Stelljes M; Kienast J; Mundhenk P; Fruehauf S; Kiehl MG; Wandt H; Theuser C; Ehninger G; Zander AR;
Eur J Haematol; 2006 Jan; 76(1):9-17. PubMed ID: 16343266
[TBL] [Abstract][Full Text] [Related]
12. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase.
Goldman JM; Majhail NS; Klein JP; Wang Z; Sobocinski KA; Arora M; Horowitz MM; Rizzo JD
J Clin Oncol; 2010 Apr; 28(11):1888-95. PubMed ID: 20212247
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors.
Champlin R; Jabbour E; Kebriaei P; Anderlini P; Andersson B; de Lima M
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1(Suppl 1):S96-100. PubMed ID: 22035758
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Allogeneic Hematopoietic Cell Transplantation in Patients With Chronic Phase CML Resistant or Intolerant to Tyrosine Kinase Inhibitors.
Yassine F; Reljic T; Moustafa MA; Iqbal M; Murthy HS; Kumar A; Kharfan-Dabaja MA
Hematol Oncol Stem Cell Ther; 2022 Mar; 15(1):36-43. PubMed ID: 33789163
[TBL] [Abstract][Full Text] [Related]
15. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L
Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic Transplantation in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on Survival: A Quasi-Experimental Study.
Özen M; Üstün C; Öztürk B; Topçuoğlu P; Arat M; Gündüz M; Atilla E; Bolat G; Arslan Ö; Demirer T; Akan H; İlhan O; Beksaç M; Gürman G; Özcan M
Turk J Haematol; 2017 Mar; 34(1):16-26. PubMed ID: 27094579
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report.
Saikia TK; Parikh PM; Tawde S; Amare-Kadam PS; Rajadhyaksha S; Chhaya S
Natl Med J India; 2004; 17(2):71-3. PubMed ID: 15141598
[TBL] [Abstract][Full Text] [Related]
18. Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era - forgotten but not gone.
Tang K; Lipton JH
Leuk Lymphoma; 2024 Jun; 65(6):705-714. PubMed ID: 38335007
[TBL] [Abstract][Full Text] [Related]
19. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
[TBL] [Abstract][Full Text] [Related]
20. Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shimoni A; Volchek Y; Koren-Michowitz M; Varda-Bloom N; Somech R; Shem-Tov N; Yerushalmi R; Nagler A
Cancer; 2015 Mar; 121(6):863-71. PubMed ID: 25387866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]